GARDNER, Mass.—New England Peptide (NEP) recently announced that it has joined with other global leaders in the proteomics field to create the Proteomics Innovation Network, an association of proteomics product and service providers designed to generate collaborative "sample to discovery" solutions across the proteomics spectrum.
"Since proteomics is growing and evolving at such a rapid pace, it is critical for leaders in the field to come together to address the greatest challenges and opportunities in proteomics," explains NEP CEO Dave Robinson. "We are optimistic that this collaboration will fast-track breakthroughs in drug discovery, personalized medicine and more."
Each of the 13 network members has complementary expertise, core technologies and infrastructure to address critical unmet needs in biomarker and drug target discovery, personalized medicine, drug profiling and selective reaction monitoring. In addition to NEP, the network includes: Australian Proteome Analysis Facility, Covaris Inc., Dualsystems Biotech, Eprogen, Focus Proteomics, Horluce BioConsulting, Innova Proteomics, Neolomed Biosciences LLC, New Liberty Proteomics, Norton Scientific and the Ontario Cancer Biomarker Network.
Founded in 1998, NEP designs and produces custom peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. The company's chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications.
"Since proteomics is growing and evolving at such a rapid pace, it is critical for leaders in the field to come together to address the greatest challenges and opportunities in proteomics," explains NEP CEO Dave Robinson. "We are optimistic that this collaboration will fast-track breakthroughs in drug discovery, personalized medicine and more."
Each of the 13 network members has complementary expertise, core technologies and infrastructure to address critical unmet needs in biomarker and drug target discovery, personalized medicine, drug profiling and selective reaction monitoring. In addition to NEP, the network includes: Australian Proteome Analysis Facility, Covaris Inc., Dualsystems Biotech, Eprogen, Focus Proteomics, Horluce BioConsulting, Innova Proteomics, Neolomed Biosciences LLC, New Liberty Proteomics, Norton Scientific and the Ontario Cancer Biomarker Network.
Founded in 1998, NEP designs and produces custom peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. The company's chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications.
